For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
The Global Info Research report includes an overview of the development of the Biologics and Biosimilars industry chain, the market status of Hospital (Monoclonal Antibodies, Interferon), Retail Pharmacy (Monoclonal Antibodies, Interferon), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biologics and Biosimilars.
Regionally, the report analyzes the Biologics and Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biologics and Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Biologics and Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biologics and Biosimilars industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Monoclonal Antibodies, Interferon).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biologics and Biosimilars market.
Regional Analysis: The report involves examining the Biologics and Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biologics and Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Biologics and Biosimilars:
Company Analysis: Report covers individual Biologics and Biosimilars players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biologics and Biosimilars This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Retail Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Biologics and Biosimilars. It assesses the current state, advancements, and potential future developments in Biologics and Biosimilars areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biologics and Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Biologics and Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Monoclonal Antibodies
- Interferon
- Insulin
- Vaccines
- Others
Market segment by Application
- Hospital
- Retail Pharmacy
- Other
Market segment by players, this report covers
- Roche
- Amgen
- AbbVie
- Sanofi
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- Biogen
- Celltrion
- Sobi
- 3SBIO
- Changchun High Tech
- Kanghong Pharma
- Innovent Biologics
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
Market segment by regions, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologics and Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologics and Biosimilars, with revenue, gross margin and global market share of Biologics and Biosimilars from 2019 to 2024.
Chapter 3, the Biologics and Biosimilars competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Biologics and Biosimilars market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics and Biosimilars.
Chapter 13, to describe Biologics and Biosimilars research findings and conclusion.